# Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine

> **NCT00923299** · PHASE1,PHASE2 · COMPLETED · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 33 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** cetuximab
- **DRUG:** trastuzumab

## Key facts

- **NCT ID:** NCT00923299
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-04
- **Final completion:** 2011-03
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2019-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923299, "Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00923299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*